In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval for the first-ever medication designed specifically to treat frostbite. Aurlumyn, an injectable medication, has been greenlit for use in adults who have suffered severe frostbite, with the primary aim of reducing the risk of toe or finger amputations.
The announcement marks a significant advancement in the field of cold-related injuries, offering a targeted therapeutic option for individuals facing severe consequences from frostbite. Clinical trials of Aurlumyn demonstrated its efficacy in mitigating the need for amputations, with patients receiving the medication showing a lower. . .